{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:30:03Z","timestamp":1786581003772,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vivex Biologics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic low-back pain is a leading cause of global disability, with degenerative disc disease (DDD) recognized as a common structural contributor. While conservative therapies may provide temporary symptom relief, they do not address the underlying degeneration of the intervertebral disc. Surgical interventions, such as spinal fusion or total disc replacement, are invasive procedures that permanently alter the anatomical structure of the vertebral motion segment. Minimally invasive intradiscal therapies have the potential to bridge the treatment gap between non-surgical management and surgery. Intradiscal delivery of nucleus pulposus (NP) allograft is intended to structurally supplement the degenerating disc and restore native disc function. Preliminary studies have suggested that a single intradiscal administration of NP allograft (VIA Disc NP) may improve pain and function in patients with lumbar discogenic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a randomized, double-blind, sham-controlled, multi-center clinical trial designed to evaluate the safety and efficacy of VIA Disc NP. Eligible participants are 22 to 85\u00a0years of age with MRI-confirmed lumbar DDD (modified Pfirrmann grade 3\u20137), axial low-back pain of at least 6\u00a0months\u2019 duration, and functional impairment unresponsive to conservative treatment. Participants are randomized in a 2:1 ratio to receive either a single injection of VIA Disc NP or a sham procedure. The primary efficacy endpoint of this superiority trial is the proportion of participants achieving a\u2009\u2265\u200930% reduction in back pain severity at 12\u00a0months. Secondary endpoints include functional improvement (ODI), quality-of-life measures (EQ-5D-5L, PGIC), and\u00a0opioid reduction. Sham participants who remain symptomatic at 12\u00a0months may cross over to receive active treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will provide level-1 evidence of the safety and efficacy of supplemental NP allograft therapy in patients with moderate to severe lumbar discogenic pain. If successful, this approach may offer a minimally invasive, durable, and structure-preserving treatment alternative to spinal fusion or disc arthroplasty in a population with limited therapeutic options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial is prospectively registered at ClinicalTrials.gov (Identifier: NCT06778447). Registered on January 16, 2025<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09826-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:06:04Z","timestamp":1780905964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of intradiscal nucleus pulposus allograft versus sham for lumbar discogenic pain associated with degenerative disc disease: study protocol for a randomized clinical trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Timothy R.","family":"Deer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierce D.","family":"Nunley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramana K.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P.","family":"Beall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy T.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron K.","family":"Calodney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Soin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan P.","family":"Lorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9954-8938","authenticated-orcid":false,"given":"Jon E.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"9826_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/pme.12082","volume":"14","author":"N Bogduk","year":"2013","unstructured":"Bogduk N, Aprill C, Derby R. Lumbar discogenic pain: state-of-the-art review. Pain Med. 2013;14:813\u201336.","journal-title":"Pain Med"},{"key":"9826_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/JPR.S441180","volume":"17","author":"MP Lorio","year":"2024","unstructured":"Lorio MP, Tate JL, Myers TJ, Block JE, Beall DP. Perspective on intradiscal therapies for lumbar discogenic pain: state of the science, knowledge gaps, and imperatives for clinical adoption. J Pain Res. 2024;17:1171\u201382.","journal-title":"J Pain Res"},{"key":"9826_CR3","doi-asserted-by":"crossref","unstructured":"Scarcia L, Pileggi M, Camilli A, et al. Degenerative disc disease of the spine: from anatomy to pathophysiology and radiological appearance, with morphological and functional considerations. J Pers Med. 2022;12.","DOI":"10.3390\/jpm12111810"},{"key":"9826_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-025-00681-8","volume":"12","author":"BT Hammoor","year":"2026","unstructured":"Hammoor BT, Lai CS, Xiong GX, et al. Intervertebral disc degeneration. Nat Rev Dis Primers. 2026;12:5.","journal-title":"Nat Rev Dis Primers"},{"key":"9826_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12891-025-08701-0","volume":"26","author":"DP Beall","year":"2025","unstructured":"Beall DP, Davis TT, Amirdelfan K, et al. Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study. BMC Musculoskelet Disord. 2025;26:437.","journal-title":"BMC Musculoskelet Disord"},{"key":"9826_CR6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/JPR.S516571","volume":"18","author":"S Costandi","year":"2025","unstructured":"Costandi S, Beall DP, Davis TT, et al. Durability of supplemental nucleus pulposus allograft in patients with lumbar discogenic pain. J Pain Res. 2025;18:1901\u20138.","journal-title":"J Pain Res"},{"key":"9826_CR7","unstructured":"DePalma MJ, Ketchum J, Queler E, et al. Does sustained hip flexion, pelvic rock, or location of low back pain predict the etiology of low back pain? An interim analysis of 170 consecutive low back pain cases. International Spine Intervention Society Annual Meeting; New Orleans, LA. Pain Med: Pain Med; 2009. p. 947\u201355."},{"key":"9826_CR8","doi-asserted-by":"crossref","unstructured":"Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain. Towards international consensus regarding minimal important change. Spine. 2008;33:90\u20134.","DOI":"10.1097\/BRS.0b013e31815e3a10"},{"key":"9826_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.spinee.2020.01.010","volume":"20","author":"AM Asher","year":"2020","unstructured":"Asher AM, Oleisky ER, Pennings JS, et al. Measuring clinically relevant improvement after lumbar spine surgery: is it time for something new? Spine J. 2020;20:847\u201356.","journal-title":"Spine J"},{"key":"9826_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain"},{"key":"9826_CR11","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.spinee.2016.01.180","volume":"16","author":"TF Fekete","year":"2016","unstructured":"Fekete TF, Haschtmann D, Kleinstuck FS, Porchet F, Jeszenszky D, Mannion AF. What level of pain are patients happy to live with after surgery for lumbar degenerative disorders? Spine J. 2016;16:S12\u20138.","journal-title":"Spine J"},{"key":"9826_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jbspin.2009.03.008","volume":"76","author":"T Pham","year":"2009","unstructured":"Pham T, Tubach F. Patient acceptable symptomatic state (PASS). Jt Bone Spine. 2009;76:321\u20133.","journal-title":"Jt Bone Spine"},{"key":"9826_CR13","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1097\/BRS.0b013e3181ae2bd4","volume":"34","author":"JM Fritz","year":"2009","unstructured":"Fritz JM, Hebert J, Koppenhaver S, Parent E. Beyond minimally important change: defining a successful outcome of physical therapy for patients with low back pain. Spine (Phila Pa 1976). 2009;34:2803\u20139.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"9826_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.spinee.2018.06.348","volume":"19","author":"CH Crawford 3rd","year":"2019","unstructured":"Crawford CH 3rd, Glassman SD, Djurasovic M, Owens RK 2nd, Gum JL, Carreon LY. Prognostic factors associated with best outcomes (minimal symptom state) following fusion for lumbar degenerative conditions. Spine J. 2019;19(2):187\u201390.","journal-title":"Spine J"},{"key":"9826_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.spinee.2016.06.010","volume":"16","author":"ML van Hooff","year":"2016","unstructured":"van Hooff ML, Mannion AF, Staub LP, Ostelo RW, Fairbank JC. Determination of the Oswestry disability index score equivalent to a \u201csatisfactory symptom state\u201d in patients undergoing surgery for degenerative disorders of the lumbar spine-a Spine Tango registry-based study. Spine J. 2016;16:1221\u201330.","journal-title":"Spine J"},{"key":"9826_CR16","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1097\/00007632-200011150-00017","volume":"25","author":"JC Fairbank","year":"2000","unstructured":"Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine. 2000;25:2940\u201352 (discussion 52).","journal-title":"Spine"},{"key":"9826_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.36076\/ppj.2021.24.465","volume":"24","author":"DP Beall","year":"2021","unstructured":"Beall DP, Davis T, DePalma MJ, et al. Viable disc tissue allograft supplementation; one- and two-level treatment of degenerated intervertebral discs in patients with chronic discogenic low back pain: one year results of the VAST randomized controlled trial. Pain Physician. 2021;24:465\u201377.","journal-title":"Pain Physician"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09826-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:09:11Z","timestamp":1786579751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09826-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9826"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09826-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6848731\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients will provide informed consent. The study was reviewed and approved by an independent Institutional Review Board (IRB), WCG (Western Copernicus Group, Cary, NC, USA) with tracking #20244769 on May 23, 2025. The trial will be conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate {24}","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not contain individual personal data from patients.","order":2,"name":"Ethics","label":"Consent for publication {32}","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TRD reports consulting for Abbott, SpineThera, Saluda Medical, Cornerloc, Boston Scientific, PainTeq, Spinal Simplicity, SPR Therapeutics, Biotronik, Aurora, and Nervonik; a patent pending with Abbott; and advisory board positions with Abbott. PDN reports a research grant from Orthofix and participation on an advisory board from 3Spine. RKN received consulting fees from Vivex, Boston Scientific, and Ferring Pharmaceuticals. DPB is a scientific advisor to Vivex Biologics and received grants or contracts from Medtronic, Medical Metrics, Avanos, Relievant, Boston Scientific, Stryker, Sollis Pharmaceuticals, Simplify Medical, Lenoss Medical, Spine BioPharma, Eliem Therapeutics, Smart Soft, Tissue Tech, Vivex, Stratus Medical, Restorative Therapies, Kolon, TissueGene, Companion Spine, and DiscGenics; royalties from VIVEX and IZI; consulting fees from Medtronic, Spineology, Merit Medical, Johnson & Johnson, IZI, Techlamed, Peterson Enterprises, Medical Metrics, Avanos, Boston Scientific, Sollis Pharmaceuticals, Simplify Medical, Stryker, Lenoss Medical, Spine BioPharma, Piramal, ReGelTec, Nanofuse, Spinal Simplicity, Pain Theory, Spark Biomedical, Micron Medical Corp, Bronx Medical, Smart Soft, Tissue Tech, RayShield, Stayble, Thermaquil, Vivex, Stratus Medical, Genesys, Abbott, Eliquence, SetBone Medical, Amber Implants, Cerapedics, Neurovasis, Varian Medical Systems, Companion Spine, DiscGenics, Discure, SpinaFX, and PainTEQ; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Artio, Sophiris, Eleven Biotherapeutics, Flow Forward, Lenoss Medical, ReGelTec, and Spark Biomedical; and support for attending meetings and\/or travel from Medtronic, ReGelTec, Nanofuse, Talosix, Spinal Simplicity, Pain Theory, Spark Biomedical, Smart Soft, Tissue Tech, Bronx Medical, Thermaquil, Vivex, Genesys, SetBone Medical, Amber Implants, Cerapedics, and SpinaFX. TTD received consulting fees from Abbott, Boston Scientific, and Biotronik and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott, Boston Scientific, and Biotronik. AKC received consulting fees from Vivex Biologics. AS and MPL report no conflicts of interest. JEB received support for medical writing from Vivex Biologics and consulting fees from Vivex.","order":3,"name":"Ethics","label":"Competing interests {28}","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"526"}}